@entity855 assay-guided chemosensitivity testing for XXXX with biopsy specimens obtained from unresectable @entity788 using endoscopic ultrasonography-guided fine-needle aspiration.

@entity1 @entity788 @entity5 @entity136 @entity855
OBJECTIVES: This study evaluates the feasibility of chemosensitivity testing by use of endoscopic ultrasonography-guided fine-needle aspiration (EUS-FNA) samples and determines the optimum cut-off value for @entity136 . METHODS: Thirty-four consecutive @entity1 with unresectable @entity788 were enrolled. Chemosensitivity (treated/control ratio: T/C ratio) was calculated as the quantity of @entity855 for a @entity5 treated with @entity136 as a percentage of that for the control. To identify the cut-off value sufficient to predict 180  days of progression-free survival (PFS), the receiver operating characteristic curve and the corresponding area under the curve (AUC) were calculated. RESULTS: The success of this assay was 88.2% (30/34); therefore, 30 @entity1 were assessable and included in the population of analyzable @entity1 .. The response was 6.7%. Median PFS was 96  days and median overall survival was 241  days, respectively. The cut-off value was determined as 74% (AUC, 0.745; p  =  0.053; 95% CI 0.485-1.005). According to this cut-off value, we predicted 180  days PFS with a sensitivity and specificity of 71.4 and 91.3%, respectively. When @entity1 were divided into two groups at T/C ratio 74%, a significant difference was found in PFS (median 77 vs. 205  days, p  =  0.0036). Moreover, T/C ratio  <  74% and decrease of CA19-9 were significant and independent prognostic factors by multivariate analysis. CONCLUSION: Chemosensitivity testing by use of EUS-FNA samples in @entity1 with unresectable @entity788 is feasible. This definition emphasizes the possibility of selecting @entity1 for whom favorable results from @entity136 treatment can be expected.
